Lupin Limited (LUPIN) — Announcement Announcement
📢 Key Event
Lupin and Natco secure U.S. FDA approval for Eribulin Mesylate Injection
💡 Investor Takeaway
This approval unlocks a $43.7 million U.S. market opportunity for Lupin's oncology portfolio.
Lupin and Natco announced U.S. FDA approval for their generic version of Eribulin Mesylate Injection, a treatment for metastatic breast cancer and liposarcoma, with estimated U.S. sales of $43.7 million in 2025. The approval enables market entry into a $43.7 million opportunity and strengthens Lupin's oncology portfolio in high-growth therapeutic areas.
📄 View Original Announcement (PDF)
About Lupin Limited (LUPIN)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Market Cap: ₹1,04,071.47 Cr
P/E: 36.2
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.